Head to Head Review: Female Health Company (The) (VERU) & The Competition

Female Health Company (The) (NASDAQ: VERU) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Female Health Company (The) to related businesses based on the strength of its risk, analyst recommendations, earnings, institutional ownership, valuation, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Female Health Company (The) and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Female Health Company (The) 0 0 2 0 3.00
Female Health Company (The) Competitors 840 3774 6796 185 2.55

Female Health Company (The) currently has a consensus price target of $5.00, indicating a potential upside of 309.84%. As a group, “Pharmaceuticals” companies have a potential upside of 24.78%. Given Female Health Company (The)’s stronger consensus rating and higher probable upside, analysts plainly believe Female Health Company (The) is more favorable than its peers.

Insider & Institutional Ownership

4.9% of Female Health Company (The) shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are held by institutional investors. 10.9% of Female Health Company (The) shares are held by insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Female Health Company (The) and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Female Health Company (The) N/A N/A -6.42
Female Health Company (The) Competitors $8.20 billion $2.68 billion -1.59

Female Health Company (The)’s peers have higher revenue and earnings than Female Health Company (The). Female Health Company (The) is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Female Health Company (The) has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Female Health Company (The)’s peers have a beta of 0.89, suggesting that their average stock price is 11% less volatile than the S&P 500.


This table compares Female Health Company (The) and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Female Health Company (The) -42.02% -16.78% -10.64%
Female Health Company (The) Competitors -2,859.74% -67.95% -9.23%


Female Health Company (The) beats its peers on 6 of the 11 factors compared.

Female Health Company (The) Company Profile

Veru Inc., formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout and sexual dysfunction. Women’s Health has product candidates for female sexual health, and advanced breast and ovarian cancers. It manufactures, markets and sells the FC2 Female Condom. FC2 provides dual protection against unintended pregnancy and sexually transmitted infections (STIs), including human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).

What are top analysts saying about Female Health Company (The)? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Female Health Company (The) and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit